» Articles » PMID: 12237434

Initiation of Hepatitis Delta Virus (HDV) Replication: HDV RNA Encoding the Large Delta Antigen Cannot Replicate

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2002 Sep 19
PMID 12237434
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The hepatitis delta virus (HDV) nucleocapsid consists of a genomic-length RNA of 1.7 kb and approximately equimolar amounts of the small and large forms of the hepatitis delta antigen (S-HDAg and L-HDAg, respectively). Since HDV RNA particles contain not only a genomic RNA species encoding S-HDAg but also an RNA species encoding L-HDAg, which is produced by an RNA-editing process, the question arises as to whether RNAs encoding either L-HDAg or S-HDAg can initiate replication. To study this, two cDNA-free transfection methods were employed: HDV RNA cotransfected with either the S-HDAg-encoding mRNA species or the ribonucleocapsid protein complex, comprising HDV RNA and recombinant S-HDAg. Results showed that the genomic-sense RNA encoding S-HDAg could promote HDV replication, whereas the L-HDAg-encoding RNA species was unable to replicate under the same conditions. The antigenomic RNA species encoding either S-HDAg or L-HDAg could not replicate by either of these procedures. In addition, L-HDAg alone could not promote replication of the genomic RNA but, by supplementing an equal amount of S-HDAg, replication occurred. These data indicate that L-HDAg-encoding RNA species are probably not involved in the initiation of HDV RNA synthesis; instead, their main function may be to serve as template for producing L-HDAg, which regulates HDV RNA synthesis and virion assembly. These results suggest that the genomic RNA species encoding S-HDAg is the only functional genome for HDV infection and explain why the presence of the edited HDV RNA encoding L-HDAg does not interfere with HDV infection.

Citing Articles

Cellular Factors Involved in the Hepatitis D Virus Life Cycle.

Thiyagarajah K, Basic M, Hildt E Viruses. 2023; 15(8).

PMID: 37632029 PMC: 10459925. DOI: 10.3390/v15081687.


Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.

Dietz-Fricke C, Tacke F, Zollner C, Demir M, Schmidt H, Schramm C JHEP Rep. 2023; 5(4):100686.

PMID: 37025462 PMC: 10071092. DOI: 10.1016/j.jhepr.2023.100686.


Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets.

Zi J, Gao X, Du J, Xu H, Niu J, Chi X Front Microbiol. 2022; 13:838382.

PMID: 35464929 PMC: 9022428. DOI: 10.3389/fmicb.2022.838382.


AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis.

Maestro S, Gomez-Echarte N, Camps G, Usai C, Suarez L, Vales A Viruses. 2021; 13(5).

PMID: 33925087 PMC: 8145145. DOI: 10.3390/v13050788.


Targeting the Host for New Therapeutic Perspectives in Hepatitis D.

Turon-Lagot V, Saviano A, Schuster C, Baumert T, Verrier E J Clin Med. 2020; 9(1).

PMID: 31947588 PMC: 7019876. DOI: 10.3390/jcm9010222.